Tyra Biosciences, Inc. (TYRA)
28.65
+3.79
(+15.25%)
USD |
NASDAQ |
Sep 04, 16:00
28.70
+0.05
(+0.17%)
Pre-Market: 20:00
Tyra Biosciences Shareholders Equity (Quarterly) : 353.66M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 353.66M |
| March 31, 2026 | 387.58M |
| December 31, 2025 | 259.18M |
| September 30, 2025 | 280.51M |
| June 30, 2025 | 302.15M |
| March 31, 2025 | 323.53M |
| December 31, 2024 | 343.15M |
| September 30, 2024 | 362.29M |
| June 30, 2024 | 376.04M |
| March 31, 2024 | 389.88M |
| December 31, 2023 | 204.26M |
| September 30, 2023 | 222.17M |
| Date | Value |
|---|---|
| June 30, 2023 | 238.57M |
| March 31, 2023 | 248.79M |
| December 31, 2022 | 257.83M |
| September 30, 2022 | 267.76M |
| June 30, 2022 | 278.85M |
| March 31, 2022 | 291.18M |
| December 31, 2021 | 301.74M |
| September 30, 2021 | 309.73M |
| June 30, 2021 | |
| March 31, 2021 | -17.52M |
| December 31, 2020 | -13.64M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| CG Oncology, Inc. | 1.029B |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 383.36M |
| Total Liabilities (Quarterly) | 29.70M |
| Debt to Equity Ratio | 0.0158 |
| Current Ratio | 14.91 |
| Net Debt Paydown Yield | 0.01% |